<DOC>
	<DOCNO>NCT02896270</DOCNO>
	<brief_summary>The trial investigates use VPA ( Valproic Acid ) treatment adult patient biopsy proven idiopathic focal segmentel glomerulosclerosis ( FSGS ) minimal change disease ( MCD ) . VPA use add-on steroid might induce clinical remission first category patient potentially reduce dose maintenance immunosuppression require maintain remission thereafter . In second category patient VPA might allow reduction even cessation immunosuppression clinical remission maintain .</brief_summary>
	<brief_title>Valproic Acid Idiopathic Nephrotic Syndrome</brief_title>
	<detailed_description>Idiopathic MCD treat disease considerable associate morbidity mortality . Current treatment option limit , limited efficacy considerable side effect profile . Recent finding murine model suggest VPA treatment early phase renal disease could halt even prevent development proteinuria progression kidney damage . VPA commonly use easy available oral antiepileptic agent favorable side effect profile compare current standard care agent podocytopathies . This trial investigate wether 1 . VPA top substitution standard care agent effective remission induction patient FSGS MCD proteinuria resistant first line therapy corticosteroid . 2 . VPA effective remission maintenance allow reduction cessation chronic immunosuppression without relapse patient frequently relapse FSGS MCD .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Nephrosis , Lipoid</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Able give inform consent Biopsy proven idiopathic FSGS MCD Organ function : Bilirubin/AST/ALT &lt; 2 ULN PLT &gt; 100.000 10*6/L INR 1.5 except antivitamin K treatment Lipase &lt; 1.5 ULN Creatinine clearance &gt; 30ml/min Contraindication VPA Secondary etiology FSGS MCD Multiple organ transplantation Currently participate another clinical trial Pregnant lactate woman Women unwilling take efficient contraceptive measure duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>idiopathic podocytopathies</keyword>
	<keyword>Neprology</keyword>
</DOC>